Director Katie Peng proposes selling 1,006 shares of Scholar Rock (SRRK).
Scholar Rock Holding Corp. director Katie Peng has filed a notice to sell 1,006 common shares of SRRK, valued at approximately $48,610, with an anticipated sale date of October 1, 2026. The proposed sale includes shares from RSU transactions on August 15 and September 15, 2026. J.P. Morgan Securities LLC is listed as the broker for this transaction.
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
Kuehn Law is encouraging investors of Scholar Rock Holding Corp (SRRK) to contact their law firm. The article is a headline-only news item from PR Newswire, indicating potential legal action or investigation related to the company.
Investigation launched into Scholar Rock's officers for possible self-dealing harming shareholders
Kuehn Law, PLLC has initiated an investigation into Scholar Rock Holding Corp's officers and directors regarding potential breaches of fiduciary duties and self-dealing that may harm shareholders. This probe could lead to shareholder damages and corporate governance reforms, prompting long-term shareholders to seek legal consultation. The case underscores broader concerns about management integrity and the protection of shareholder interests at the company.
Net income of Scholar Rock Holding Corp. – HAN:2QK
The article focuses on the net income of Scholar Rock Holding Corp. (HAN:2QK) as listed on the Hannover Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content is primarily a data placeholder within a financial platform, showing basic financial information for the company.
Form 4 Scholar Rock Holding Corp For: 26 September By Investing.com
This Investing.com article announces the filing of a Form 4 for Scholar Rock Holding Corp on September 26, 2026. The content is very brief and primarily serves as a placeholder or notification of the regulatory filing, without providing details about the filing itself. The majority of the page is filled with navigation links, market data, and unrelated news summaries.
No common shares appear in Scholar Rock (SRRK) COO Keith Woods’s reported position after a gift to a trust.
Scholar Rock Holding Corp (SRRK) COO Keith Woods gifted 48,034 common shares to the RKW Irrevocable Trust on September 24, 2026. Following this transaction, Woods's reported position lists 0 common shares, but includes 122,021 time-based RSUs and 450,000 performance- and time-based RSUs. He disclaimed beneficial ownership of the trust shares except for his pecuniary interest.
Scholar Rock added to Wedbush's Best Ideas List
Wedbush has added Scholar Rock Holding Corp. (SRRK) to its Best Ideas List, citing the company's strong position for commercial growth in the neuromuscular sector. The firm projects a $70 price target for SRRK, indicating a potential 44% upside from its previous closing price. This positive outlook suggests confidence in Scholar Rock's future performance.
Wedbush Rates Scholar Rock (SRRK) Outperform Amid Attractive Price-to-Sales Opportunity
Wedbush has assigned an "Outperform" rating to Scholar Rock (SRRK), citing its promising neuromuscular pipeline and recent product launch, ISEMBYLD, as key growth drivers. Despite the company's current unprofitability and high Price-to-Sales ratio of 30.4x, Wedbush believes recent stock weakness presents an entry point for investors. The article highlights SRRK's moderate financial strength but notes a low GF Score of 29/100 due to profitability and momentum challenges, alongside mixed insider sentiment.
No payment changed hands when Scholar Rock (SRRK) CEO David Hallal transferred 36,652 shares to a family trust.
Scholar Rock Holding Corp (SRRK) CEO David Hallal transferred 36,652 common shares to The Hallal Family Irrevocable Trust-2021 on September 21, 2026, without any monetary exchange. After this transaction, Hallal's reported direct and indirect holdings totaled 1,602,382 shares, including common stock and various RSUs, with the trust directly holding the gifted shares. The Form 4 filing specifies that the CEO disclaims beneficial ownership of the securities held by the trusts beyond his pecuniary interest.
Bank of America Corp DE Takes $53.47 Million Position in Scholar Rock Holding Corporation $SRRK
Bank of America Corp DE has acquired a new stake of 972,257 shares in Scholar Rock Holding Corporation (NASDAQ:SRRK), valued at approximately $53.47 million, representing about 0.8% of the company. Institutional investors now collectively own 91.08% of SRRK. Analyst sentiment remains positive, with a consensus "Buy" rating and an average price target of $66.00, while the company reported a quarterly EPS of -$0.84, meeting analyst expectations.
SRRK Maintains Overweight Rating by JP Morgan -- Price Target Ra
JP Morgan has reiterated an "Overweight" rating for Scholar Rock Holding Corp (SRRK), increasing its price target from $63.00 to $70.00. Despite this positive analyst outlook driven by its innovative pipeline in neuromuscular diseases, the company's GF Score™ is low at 29/100, indicating below-average performance in profitability and growth. Investors are cautioned due to the high price-to-sales ratio and mixed sentiment from institutional investors and insider selling activity.
Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?
Scholar Rock Holding Corporation (SRRK) received FDA approval for ISEMBYLD to treat spinal muscular atrophy (SMA) as an add-on to existing therapies. The drug demonstrated motor benefits in clinical trials, suggesting a complementary role to current treatments. However, its commercial success hinges on patient access, payer coverage, and managing the risk of fractures as a side effect.
Scholar Rock (NASDAQ: SRRK) Updates FDA Safety Requirements for ISEMBYLD Post-Approval
Scholar Rock (NASDAQ: SRRK) announced updates to the FDA's post-approval safety requirements for its drug ISEMBYLD, which is approved for spinal muscular atrophy. The company clarified that it is mandated to conduct a pregnancy safety study and report all serious and non-serious fracture cases globally as alert reports, correcting previous statements made during an investor call. Scholar Rock has committed to complying with these FDA requirements.
Form 8K Scholar Rock Holding Corp For: 15 September By Investing.com
This article reports on the filing of a Form 8K by Scholar Rock Holding Corp on September 15. The brief announcement provides no further details about the content of the filing. It includes the stock symbol SRRK and notes a slight decrease in its value.
SRRK Stock News Today | Earnings, Events & Price Alerts
This article provides recent news and events related to SRRK stock (Scholar Rock). Key updates include the FDA approval of Isembyld for SMA treatment, its fast-track and orphan drug designations, and a required post-marketing pregnancy safety study. The stock saw a 4% decline to $49.97 following the event details.
Barclays downgrades Scholar Rock stock rating on valuation
Barclays downgraded Scholar Rock (NASDAQ:SRRK) to Equalweight from Overweight and raised its price target to $58 from $55 following the FDA approval of apitegromab (Isembyld). The firm noted that the risk-reward profile is now more balanced, with future upside dependent on strong commercial execution and pipeline expansion beyond spinal muscular atrophy. Despite the approval, the company remains unprofitable, underscoring the importance of successful commercialization.
Timothy Springer-backed biotech hits milestone: FDA approves first-of-its-kind SMA therapy
Scholar Rock, a Cambridge-based biotech company backed by Harvard immunologist Timothy Springer, has received FDA approval for its first drug. This therapy is a first-of-its-kind treatment for muscle loss associated with spinal muscular atrophy (SMA). The approval marks a significant milestone for the company and its investors.
Form 8K Scholar Rock Holding Corp For: 14 September By Investing.com
This article reports on the filing of a Form 8K by Scholar Rock Holding Corp on September 14, 2026. The brief entry provides the company name and filing date, without further details on the content of the Form 8K. The article is published by Investing.com, a financial markets news service.
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
The FDA has approved Scholar Rock's ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy (SMA) in patients aged 2 and older, marking it as the first muscle-targeted therapy to improve motor function in individuals already on SMN2-targeted drugs. This approval, backed by positive Phase 3 SAPPHIRE study results, also earned Scholar Rock a Rare Pediatric Disease Priority Review Voucher. The company has begun the U.S. commercial launch of ISEMBYLD, which targets promyostatin and latent myostatin to inhibit myostatin activation.
Why is Scholar Rock stock surging 9% today?
Scholar Rock Holding Corp (SRRK) stock surged over 9% after the FDA approved ISEMBYLD for spinal muscular atrophy, making it the first muscle-targeted treatment for the condition. This approval, which came ahead of schedule and with a broad label, transformed Scholar Rock into a commercial biopharmaceutical company. Analysts responded by significantly raising price targets, further boosting investor confidence despite a broader market downturn.
BMO reiterates Scholar Rock stock Outperform on SMA drug uptake
BMO Capital has reiterated an Outperform rating and a $76.00 price target for Scholar Rock (NASDAQ: SRRK) due to the anticipated broad usage of its SMA drug, apitegromab. A physician survey indicated significant potential for the drug in combination with SMN-directed therapy, with most surveyed neurologists planning to prescribe it upon approval. Despite the stock's 75% surge over the past year, InvestingPro data suggests it may be overvalued compared to its Fair Value estimate.
Bank of New York Mellon Corp Acquires New Shares in Scholar Rock Holding Corporation $SRRK
Bank of New York Mellon Corp has acquired 365,218 shares of Scholar Rock Holding Corporation (NASDAQ:SRRK), valued at approximately $20.1 million, establishing a 0.30% stake in the company. Institutional investors now collectively own 91.08% of Scholar Rock, which has a consensus "Buy" rating and an average price target of $58.77 from Wall Street analysts. The clinical-stage biotech recently reported quarterly EPS of -$0.84, aligning with analyst expectations, and its stock opened near its 52-week high at $57.80.
Scholar Rock Holding Corp stock hits 52-week high at 58.52 USD
Scholar Rock Holding Corp (SRRK) stock recently reached a 52-week high of $58.52, reflecting a 59% total return over the past year and a 74.02% one-year change. Despite appearing overvalued, the company reported a narrower-than-expected Q2 loss and is on track for a U.S. regulatory decision for its lead drug, apitegromab, by September 30. Analyst firms BMO Capital and H.C. Wainwright have reiterated "Outperform" and "Buy" ratings respectively, with price targets of $76.00 and $65.00.
Scholar Rock to Present at Upcoming Investor Conferences
Scholar Rock, a biopharmaceutical company, announced its participation in two upcoming investor conferences: the Cantor 2026 Global Healthcare Conference and the Citi 2026 BioPharma Back to School Conference. Management will engage in fireside chats at both events in New York, NY, on September 9 and September 10, 2026, respectively. Webcasts of these presentations will be available on the company's investor relations website.
Scholar Rock Holding Corp stock hits 52-week high at 58.52 USD
Scholar Rock Holding Corp (SRRK) reached a 52-week high of $58.52, with shares currently trading just 1% below this peak, reflecting a 59% total return over the past year and a 74.02% 1-year change. Despite this, InvestingPro data suggests the stock is overvalued relative to its Fair Value estimate. Recent news includes a narrower-than-expected Q2 loss and progress on its lead drug apitegromab, with analysts reiterating Buy/Outperform ratings.
BMO reiterates Scholar Rock stock rating on BLA site change
BMO Capital reiterated an Outperform rating and $76.00 price target on Scholar Rock (NASDAQ:SRRK) after the company removed the Catalent facility from its apitegromab BLA application. BMO believes this removal is unlikely to surprise investors and that FDA approval timelines remain on track for a decision by September 30. Despite five analysts revising earnings upwards, InvestingPro's Fair Value analysis suggests the stock might be overvalued.
Scholar Rock (SRRK) Is Up 8.5% After De-Risking Apitegromab’s Global Filing Pathway - Has The Bull Case Changed?
Scholar Rock (SRRK) shares rose 8.5% after the company announced de-risking moves for its drug apitegromab's global filing pathway. These include removing a contract manufacturer from the U.S. BLA, planning a resubmission in Europe with an alternate facility, and gaining Japanese regulatory alignment for filing without local trials. This significantly reduces operational risk for the global rollout of apitegromab and clarifies the path to key markets, with analysts forecasting substantial revenue and earnings growth by 2029.
Scholar Rock removes Catalent facility from SMA drug application
Scholar Rock has removed Catalent Indiana LLC as a commercial fill-finish facility from its Biologics License Application for spinal muscular atrophy treatment in the U.S. The company made this change following the FDA's "Official Action Indicated" classification of Catalent Indiana's April 2026 inspection. Scholar Rock expects an FDA decision by September 30, 2026, and plans to resubmit its European application with an alternate, U.S.-based facility.
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing
Scholar Rock (SRRK) shares rose after the company removed a controversial Novo Nordisk-owned manufacturing plant, Catalent Indiana, from its U.S. FDA application for its spinal muscular atrophy drug, apitegromab. This move comes after a previous FDA rejection due to manufacturing observations at that facility. Scholar Rock expects a decision by September 30, with an alternate U.S. manufacturing site ready for immediate launch if approved, and is also refiling in Europe.
Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
Scholar Rock announced significant regulatory progress for apitegromab across the U.S., Europe, and Japan. The company successfully removed Catalent Indiana LLC as a fill-finish facility from its U.S. Biologics License Application (BLA) for spinal muscular atrophy (SMA) and is prepared for a U.S. launch by the September 30, 2026 PDUFA date. Additionally, Scholar Rock withdrew and will resubmit its European Marketing Authorisation Application (MAA) with an alternate facility and plans to submit a Japanese New Drug Application (JNDA) by year-end 2026, as no additional clinical studies are required in Japan.
Scholar Rock advances apitegromab FDA review
Scholar Rock is proceeding with the FDA review of its apitegromab Biologics License Application for spinal muscular atrophy, having removed Catalent Indiana as a fill-finish facility and replaced it with an alternate. The FDA review is on track for a September 30, 2026 PDUFA date. The company also plans to resubmit its European application and submit a Japanese application by the end of 2026, with commercial supply available for a potential U.S. launch.
Scholar Rock is prepared to launch its SMA drug if FDA approves by Sept. 30
Scholar Rock is prepared to launch its spinal muscular atrophy (SMA) drug, apitegromab, in the U.S. if the FDA approves it by the September 30, 2026 PDUFA date. The company has successfully addressed regulatory concerns by removing a problematic fill-finish facility from its Biologics License Application (BLA) and will resubmit its European application with an alternate facility. Scholar Rock also plans to submit a Japanese New Drug Application (JNDA) by year-end 2026, as Japan's PMDA has agreed no additional clinical studies are required.
Scholar Rock Holding (SRRK) After Apitegromab Progress Is The Stock Already Fully Valued
Scholar Rock Holding (SRRK) is gaining attention due to progress with its apitegromab program and expansion into new neuromuscular disease studies, leading to significant stock price appreciation. Despite a "most popular narrative" suggesting it's 4.7% undervalued at $59.31, another perspective highlights that the stock appears expensive with a P/B ratio of 27.1x compared to peers. The company continues to report losses and has no revenue, making its investment case highly dependent on timely regulatory approvals and successful market adoption of apitegromab.
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab
Scholar Rock is anticipating a September 30 FDA decision for its investigational spinal muscular atrophy (SMA) drug, apitegromab. The drug, which targets latent myostatin, could be the first muscle-targeted therapy approved for SMA, and the company has resubmitted its application after resolving manufacturing observation issues with an alternate facility. Scholar Rock is also exploring the drug's potential for facioscapulohumeral muscular dystrophy (FSHD) and building commercial capabilities for a potential U.S. launch.
Redmile Group (SRRK) updates Scholar Rock stake to 3.6% of common stock
Redmile Group, LLC, Jeremy C. Green, and RedCo II Master Fund, L.P. have filed an updated Schedule 13G/A, disclosing that Redmile and Green collectively report beneficial ownership of 4,311,092 shares of Scholar Rock common stock, representing 3.6% of the class. This ownership is held by investment vehicles managed by Redmile, with both Redmile and Green exercising shared voting and dispositive power. RedCo II Master Fund, L.P. reports 0 shares.
12 New Hires Receive 51,947 Scholar Rock Equity Awards
Scholar Rock (NASDAQ: SRRK) announced that it granted inducement equity awards totaling 51,947 shares of common stock to twelve new employees. These awards, which include both stock options and restricted stock units, are part of the company's 2022 Inducement Equity Plan, designed to attract new talent under Nasdaq Listing Rule 5635(c)(4). The grants aim to align new hires' interests with company performance while adhering to specific vesting schedules.
SRRK Maintains by JP Morgan -- Price Target Raised to $63.00
JP Morgan maintained an "Overweight" rating for Scholar Rock Holding Corp (SRRK) and raised its price target from $56.00 to $63.00, indicating a positive outlook. Despite this, the company has a low GF Score™ of 29/100 due to profitability and growth concerns, along with significant insider selling. Investors are advised to exercise caution due to the high price-to-sales ratio and lack of intrinsic value data.
Invus reports 8.0% stake in Scholar Rock (SRRK) through 9.6M shares
Invus Public Equities, L.P. and associated entities have reported an 8.0% beneficial ownership stake in Scholar Rock Holding Corporation (SRRK), totaling 9,575,013 shares of common stock. This is detailed in an amended Schedule 13G filing, which states that the shares were acquired for passive investment purposes and not to influence control of Scholar Rock. The ownership calculation is based on 119,828,338 shares outstanding as of May 4, 2026.
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule
Scholar Rock Holding Corporation announced that the FDA review of its lead drug, apitegromab for spinal muscular atrophy, will proceed solely with its secondary fill-finish facility after an issue with its primary manufacturing site. Despite this change, the company confirmed that the Prescription Drug User Fee Act (PDUFA) action date of September 30 remains on schedule. Scholar Rock has secured a robust inventory from the alternative U.S.-based site to ensure supply readiness upon regulatory approval.
Bank of America Corp DE Buys 286,126 Shares of Scholar Rock Holding Corporation $SRRK
Bank of America Corp DE increased its stake in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 27.2% in the first quarter, adding 286,126 shares to hold a total of 1.34 million shares valued at approximately $65.7 million. Other institutional investors also adjusted their positions, with overall institutional ownership at 91.08%. Despite some insider sales for tax obligations, analysts maintain a "Buy" consensus rating with an average price target of $56.79, as Scholar Rock reported quarterly EPS matching expectations.
SRRK Reiterated by Wedbush -- Maintains Price Target at $58.00
Wedbush analyst David Nierengarten has reiterated an 'Outperform' rating for Scholar Rock Holding (SRRK) and maintained a $58.00 price target. Despite this, the company has a low GF Score™ of 29/100, indicating financial weaknesses, particularly in profitability and growth, and shows signs of potential overvaluation based on its high Price-to-Sales ratio and recent insider selling.
Scholar Rock's (SRRK) Outperform Rating Reiterated at Wedbush
Wedbush has reiterated an "Outperform" rating for Scholar Rock (SRRK) with a $58 price target, indicating a potential 12.45% upside. The company is near its 52-week high, and the analyst consensus remains "Buy" with an average target of $56.79. Institutional investors hold a significant stake, with recent insider sales primarily for tax obligations related to equity awards.
SRRK Reiterated by HC Wainwright & Co. -- Price Target Maintained at $65
HC Wainwright & Co. has reiterated its "Buy" rating for Scholar Rock Holding (SRRK), maintaining a price target of $65.00, suggesting a potential upside of 23% from its current price of $52.97. Despite this positive analyst outlook, the company has a low GF Score™ of 29/100, indicating underperformance, particularly in profitability, and insider activity shows $0.9 million in shares sold over the last three months. Investors are advised to exercise caution due to these mixed signals.
Scholar Rock Holding Corporation (SRRK) Stock Price, News, Quote & History
This article provides a detailed overview of Scholar Rock Holding Corporation (SRRK), including its current stock price, financial data, and company profile. It highlights SRRK's focus on developing treatments for neuromuscular diseases and solid tumors, showcasing its key pipeline products and recent performance metrics compared to the S&P 500. The company's latest analyst ratings and financial statistics are also presented.
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
Scholar Rock announced that the FDA review of its apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) will proceed with a second fill-finish facility, following an Official Action Indicated (OAI) classification for their initial facility, Catalent Indiana. The company expects a potential FDA approval by the September 30, 2026, PDUFA action date, with a robust commercial supply ready for packaging. Scholar Rock is also engaging with the European Medicines Agency (EMA) regarding the inclusion of this second facility in their Marketing Authorisation Application (MAA).
Form 8K Scholar Rock Holding Corp For: 6 August By Investing.com
This article briefly reports on the filing of Form 8K by Scholar Rock Holding Corp for August 6. It mentions the company's stock symbol, SRRK, and includes a minor positive percentage change in its stock value. The content is primarily a placeholder for the SEC filing itself.
Scholar Rock (NASDAQ:SRRK) Releases Earnings Results, Meets Estimates
Scholar Rock (NASDAQ:SRRK) reported quarterly earnings of ($0.84) per share, meeting analyst estimates, an improvement from ($0.98) per share a year ago. The company's U.S. approval for apitegromab is still targeted for September 30, despite delays in European approval due to FDA classification uncertainties regarding a Catalent Indiana facility. Scholar Rock ended the quarter with $492 million in liquidity and saw its shares rise by 10% following the results.
Scholar Rock Holding Corp 2Q 2026: Net loss $(215.4M), EPS $(1.67) — 10-Q Summary
Scholar Rock Holding Corp (SRRK) reported a consolidated net loss of $(215.4M) for the six months ended June 30, 2026, with a basic and diluted loss per share of $(1.67). The company recorded no product or commercial sales revenue during this period. Key business highlights include the FDA's acceptance of a resubmitted BLA for apitegromab with a PDUFA date of September 30, 2026, positive Phase 3 SAPPHIRE results for non-ambulatory SMA, and ongoing investment in commercial infrastructure for a potential product launch.
Earnings call transcript: Scholar Rock tops Q2 2026 EPS view, shares rise premarket
Scholar Rock reported better-than-expected Q2 2026 earnings per share and confirmed its lead drug apitegromab is on track for a U.S. regulatory decision by September 30, leading to a premarket stock increase. The company highlighted its readiness for launch with a second fill-finish facility and a strong financial position, while also advancing its anti-myostatin pipeline. Executives expressed confidence in the FDA review process and their commercial preparedness for both U.S. and European markets.
Scholar Rock Q2 2026 Earnings Call Transcript
Scholar Rock provided its Q2 2026 earnings update, highlighting that U.S. approval for apitegromab remains on track for September 30th despite regulatory uncertainty regarding the Catalent Indiana facility. The company has secured an independent second fill-finish facility, whose data package has been submitted to the FDA and is progressing well. Commercial launch preparations are advanced in the U.S. and Europe, with significant financial strength to support these initiatives and continued development of their anti-myostatin pipeline.
